TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36299885

Group type: EXPERIMENTAL
Intervention: DEX 200 μg combined with sufentanil 150 μg for PCA
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: DEX 400 μg combined with sufentanil 150 μg for PCA
Number of subjects: 210

Group type: COMPARATOR
Intervention: DEX 0 μg combined with sufentanil 150 μg for PCA
Number of subjects: 210
Study: 32607683

Group type: EXPERIMENTAL
Intervention: 1 µM of DPI (diphenyleneiodonium)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 nM of PMA (phorbol 12‐myristate 13‐acetate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ham's F10 (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.1% DMSO (vehicle)
Number of subjects: 40
Study: 35638321

Group type: EXPERIMENTAL
Intervention: taVNS (30-min stimulation via tragus)
Number of subjects: 54

Group type: COMPARATOR
Intervention: sham stimulation (30-min stimulation via earlobe)
Number of subjects: 54
Study: 34556563

Group type: EXPERIMENTAL
Intervention: Blended learning (individual preparation with a course handbook and videoclips, plus a single face-to-face session)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Face-to-face instruction (2 face-to-face sessions)
Number of subjects: 163
Study: 32916658

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (n = 14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (Cr and placebo)
Number of subjects: 27
Study: 34331752

Group type: EXPERIMENTAL
Intervention: Auricular acupressure therapy at the Shen Men point and endocrine point bilaterally
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham acupressure at a sham point bilaterally
Number of subjects: 58
Study: 33430844

Group type: EXPERIMENTAL
Intervention: Lower-limb focussed intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Trunk-focussed intervention
Number of subjects: 27
Study: 32702774

Group type: EXPERIMENTAL
Intervention: Complicated grief assessment in elderly individuals who experienced grief
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Assessment of CG prevalence based on demographic factors
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Assessment of CG prevalence based on deceased's characteristics
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Comparison of CG prevalence in depressed vs non-depressed participants
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Gender comparison in CG incidence
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Depression severity comparison in CG incidence
Number of subjects: 247
Study: 34311754

Group type: EXPERIMENTAL
Intervention: Community-based HIV counselling and testing (CBCT) platforms for PrEP initiation
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Adherence support interventions
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Qualitative investigations
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Cost and scalability evaluations
Number of subjects: 480
Study: 32172521

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate gel 0.38%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 35045859

Group type: EXPERIMENTAL
Intervention: Nutrition-sensitive homestead food production (HFP) program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 32803791

Group type: EXPERIMENTAL
Intervention: Intra-operative methadone
Number of subjects: 137

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 137
Study: 32886727

Group type: EXPERIMENTAL
Intervention: Professional lactation support (frequency, duration, and form)
Number of subjects: 159
Study: 34617303

Group type: EXPERIMENTAL
Intervention: Behavioural activation (BA) + Antidepressant (AD)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Trial-based cognitive therapy (TBCT) + Antidepressant (AD)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 76
Study: 33725856

Group type: EXPERIMENTAL
Intervention: Usual care + acupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 34245614

Group type: EXPERIMENTAL
Intervention: 25G Franseen needle
Number of subjects: 88

Group type: COMPARATOR
Intervention: 22G Franseen needle
Number of subjects: 88
Study: 615729350

Group type: EXPERIMENTAL
Intervention: EBUS-FNA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard endoscopic methods (EBB, TBLB, TBNA)
Number of subjects: 100
Study: 34967942

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 0
Study: 33181672

Group type: EXPERIMENTAL
Intervention: Intelligent rehabilitation assistant system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 50
Study: 35703373

Group type: EXPERIMENTAL
Intervention: Combination of clobetasol 0.05% lotion and oral NAC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of clobetasol 0.05% lotion and oral PTX
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clobetasol 0.05% lotion
Number of subjects: 30
Study: 34503977

Group type: EXPERIMENTAL
Intervention: Ripretinib 150 mg once daily
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 35943885

Group type: EXPERIMENTAL
Intervention: Holmium Laser Enucleation of the Prostate (HoLEP)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Bipolar Plasmakinetic Enucleation of the Prostate (BPEP)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Both HoLEP and BPEP
Number of subjects: 181
Study: 33120891

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) - 3-min exposure to −120 C, twice a day for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 20
Study: 36270928

Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation therapy for 5 min (L group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined treatment of foot soak and lavender oil inhalation therapy (FL group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Foot soak treatment for 20 min (F group)
Number of subjects: 45
Study: 33571004

Group type: EXPERIMENTAL
Intervention: Formal volunteering (at least 60 minutes per week for 6 months)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Control (no volunteering)
Number of subjects: 445
Study: 33992747

Group type: EXPERIMENTAL
Intervention: Message highlighting the risk of disease transmission from factory farms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Message highlighting the threat to worker's health created by factory farms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional messages highlighting environmental, personal health, or animal welfare implications of factory farmed meat consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Messages highlighting personal health benefits of reduced meat consumption
Number of subjects: 0
Study: 32527941

Group type: EXPERIMENTAL
Intervention: Chemotherapy and targeted therapy
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Mean CTC count
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Dose-modifications (increased and reduced)
Number of subjects: 451
Study: 36160398

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg kg−1) and butorphanol (20 μg kg−1)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Midazolam (0.05 mg kg−1) and butorphanol (20 μg kg−1)
Number of subjects: 56
Study: 32085907

Group type: EXPERIMENTAL
Intervention: Multi-modal intervention (cognitive training, mindfulness meditation, and aerobic exercise) over 16 weeks
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Multi-modal intervention
Number of subjects: 424
Study: 35717239

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) using PREVENA PLUS™ Incision Management System
Number of subjects: 154

Group type: COMPARATOR
Intervention: Conventional wound dressing
Number of subjects: 154
Study: 33409971

Group type: EXPERIMENTAL
Intervention: RT combined with whey protein supplementation (RTP+PRO)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: RT combined with placebo (RTP)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (PRO)
Number of subjects: 63
Study: 35906659

Group type: EXPERIMENTAL
Intervention: Structured and individualized exercise intervention (9-month multimodal exercise program, 6 months supervised twice a week, followed by 3 months with one supervised and one unsupervised session)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Structured and individualized exercise intervention
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (standard medical care, general written physical activity advice, and an activity tracker without structured exercise program)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 350
Study: 33509840

Group type: EXPERIMENTAL
Intervention: Unite for a Better Life (UBL) intervention delivered to men
Number of subjects: 4379

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4379
Study: 32780747

Group type: EXPERIMENTAL
Intervention: Mass-media campaign (televised for ten days)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Not applicable (control group who did not see the campaign)
Number of subjects: 702
Study: 35580976

Group type: EXPERIMENTAL
Intervention: Anifrolumab (300 mg every 4 weeks for 48 weeks)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study: 35178149

Group type: EXPERIMENTAL
Intervention: Training using the adapted Pathfinder International Teaching Package on the use of misoprostol in the management of PPH
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study: 32931497

Group type: EXPERIMENTAL
Intervention: Development group
Number of subjects: 6172

Group type: EXPERIMENTAL
Intervention: Validation group
Number of subjects: 6172
Study: 35175171

Group type: EXPERIMENTAL
Intervention: Health Promotion Program for Children with Asthma (HPPCA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no further education)
Number of subjects: 74
Study: 34475811

Group type: EXPERIMENTAL
Intervention: Video encouraging digital social activity
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Video sensitizing to COVID‐19 related stigma
Number of subjects: 988

Group type: COMPARATOR
Intervention: Informational sheet only
Number of subjects: 988
Study: 35247871

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg intravenously; once every 2 weeks for up to 12 months)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study: 32977820

Group type: EXPERIMENTAL
Intervention: Matrix Model treatment combined with MPH
Number of subjects: 100

Group type: COMPARATOR
Intervention: Matrix Model treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: MPH 10mg/day in the first month, 7.5mg/day in the second month and 5mg/day in the third month
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 35587607

Group type: EXPERIMENTAL
Intervention: Conexiones program (telephone-delivered cancer parenting education)
Number of subjects: 18
Study: 34329624

Group type: EXPERIMENTAL
Intervention: Usual care plus doxycycline (200 mg on day 1, then 100 mg once daily for the following 6 days)
Number of subjects: 2508

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 2508

Group type: EXPERIMENTAL
Intervention: Usual care plus doxycycline
Number of subjects: 2508
Study: 36105246

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery for OA
Number of subjects: 236
Study: 33913215

Group type: EXPERIMENTAL
Intervention: Presence of sleep disorders
Number of subjects: 351932

Group type: EXPERIMENTAL
Intervention: Non-organic sleep disorders, hypersomnia, and sleep apnea
Number of subjects: 351932

Group type: EXPERIMENTAL
Intervention: Sleep disorders
Number of subjects: 351932
Study: 32590780

Group type: EXPERIMENTAL
Intervention: Five-step cervical vertebra rehabilitation exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Basic nursing measures
Number of subjects: 90
Study: 35441345

Group type: EXPERIMENTAL
Intervention: Systemic treatment initiated in 87 patients (73% of relapsed patients)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Local therapy (irradiation or surgical intervention) in 27 patients (23% of relapsed patients)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Early relapse (< 6 months)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Microsatellite-unstable (MSI) tumor status
Number of subjects: 246
Study: 32781050

Group type: EXPERIMENTAL
Intervention: Exercise training with medical air
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Exercise training with supplemental oxygen
Number of subjects: 29
Study: 33108201

Group type: EXPERIMENTAL
Intervention: Anti-GroEL antibody
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anti-CagA antibody
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anti-HP1118/Ggt, Anti-HP0516/HsIU, Anti-HP0243/NapA, Anti-HP1293/RpoA, Anti-HP0371/FabE, Anti-HP0875/KatA antibodies
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Model with anti-Ggt, anti-HslU, anti-NapA, and anti-CagA
Number of subjects: 100
Study: 32100498

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment at specific acupuncture points (Fengshi, Futu, Zusanli, Shangjuxu, Fenglong, Xuanzhong, Diji, Sanyinjiao) for 20-30 min, twice a day for 7 days.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Routine rehabilitation treatment (control group).
Number of subjects: 140
Study: 35226095

Group type: EXPERIMENTAL
Intervention: Motivational plus family weight loss program (M + FWL)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Comprehensive health education control program
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Online tailored program
Number of subjects: 241

Group type: COMPARATOR
Intervention: Online control program
Number of subjects: 241
Study: 34831600

Group type: EXPERIMENTAL
Intervention: Modular coordinating case management
Number of subjects: 852

Group type: COMPARATOR
Intervention: Supported self-management
Number of subjects: 852
Study: 32178648

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking intervention (6-month program with 3 months of pedometers and weekly step count targets)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 60
Study: 32822222

Group type: EXPERIMENTAL
Intervention: Microwave ablation, radiotherapy, and chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chemotherapy with pemetrexed disodium or gemcitabine hydrochloride, cisplatin chemotherapy, and conventional radiotherapy
Number of subjects: 100
Study: 32507902

Group type: EXPERIMENTAL
Intervention: N-wave measurement
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: PhNR measurement
Number of subjects: 59
Study: 35543941

Group type: EXPERIMENTAL
Intervention: Head acupuncture combined with exercise therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 64
Study: 33594766

Group type: EXPERIMENTAL
Intervention: Compression garment (21–22 mmHg) worn during and for 6 h after exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-compressed leg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Compressed leg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both legs (compressed and non-compressed)
Number of subjects: 16
Study: 32160125

Group type: EXPERIMENTAL
Intervention: Collagen matrix dressing (Tebaderm)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Saline-moistened gauze dressing (control)
Number of subjects: 61
Study: 34228612

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (an anabolic steroid) in combination with vitamin D
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no anabolic steroid treatment)
Number of subjects: 64
Study: 32100946

Group type: EXPERIMENTAL
Intervention: Guideline-directed LVAD destination therapy (GD-LVAD-DT) using the HeartMate 3 (HM3) continuous flow pump
Number of subjects: 80

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 80
Study: 34389340

Group type: EXPERIMENTAL
Intervention: Surgery (esophagectomy with 2‐ or 3‐field lymph node dissection)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Chemoradiotherapy (2 courses of 5‐fluorouracil 700 mg/m2 on days 1‐4 and cisplatin 70 mg/m2 on day 1 every 4 weeks with concurrent radiation 60 Gy)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 368
Study: 35730768

Group type: EXPERIMENTAL
Intervention: Basic cluster set protocol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional set protocol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Undulating cluster protocols
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All protocols
Number of subjects: 10
Study: 33909587

Group type: EXPERIMENTAL
Intervention: PsyCovidApp (n=248)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Control app (n=234)
Number of subjects: 482
Study: 32475278

Group type: EXPERIMENTAL
Intervention: Microorganism-directed oral antibiotics for three months
Number of subjects: 142

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 142
Study: 33661990

Group type: EXPERIMENTAL
Intervention: iFlash3000 CLIA analyzer for measuring IgM and IgG titers against SARS-CoV-2
Number of subjects: 199
Study: 32565469

Group type: EXPERIMENTAL
Intervention: Early cryoprecipitate transfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 35273807

Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Intervention (BMI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both BMI and HEP
Number of subjects: 55
Study: 32301166

Group type: EXPERIMENTAL
Intervention: Manual acupuncture at acupoints LI 10 and LI 11 on the affected side
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham laser acupuncture at acupoints LI 10 and LI 11
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 96
Study: 32577927

Group type: EXPERIMENTAL
Intervention: Positive learner handover (LH)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Negative learner handover (LH)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No learner handover (LH)
Number of subjects: 42
Study: 32056873

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg once daily during the open-label period
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg, 10 mg, or 20 mg
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1106
Study: 35166327

Group type: EXPERIMENTAL
Intervention: Real-time, personalized chat messaging on relapse prevention via WhatsApp for 3 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Generic text messaging on the harms of smoking and benefits of quitting for 3 months
Number of subjects: 108
Study: 33184726

Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy
Number of subjects: 750

Group type: COMPARATOR
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 750
Study: 32050207

Group type: EXPERIMENTAL
Intervention: Anterior penetrating incisions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intrastromal arcuate incisions
Number of subjects: 50
Study: 37587599

Group type: EXPERIMENTAL
Intervention: Amulet
Number of subjects: 1878

Group type: COMPARATOR
Intervention: Watchman
Number of subjects: 1878
Study: 33559576

Group type: EXPERIMENTAL
Intervention: Unicortical locked plate and screw fixation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bicortical non-locked plate and screw fixation
Number of subjects: 16
Study: 33657185

Group type: EXPERIMENTAL
Intervention: Peer-led mental health intervention
Number of subjects: 20
Study: 32504862

Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Grade II-IV acute GVHD
Number of subjects: 80
Study: 36010995

Group type: EXPERIMENTAL
Intervention: Tapentadol (TP) 50 to 500 mg/day
Number of subjects: 114

Group type: COMPARATOR
Intervention: Tapentadol plus Duloxetine (DLX) 60 to 120 mg/day
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Tapentadol (TP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Tapentadol plus Duloxetine (DLX)
Number of subjects: 114
Study: 32732104

Group type: EXPERIMENTAL
Intervention: High-intensity cycle-based exercise
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycle-based exercise
Number of subjects: 99

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 99
Study: 34627829

Group type: EXPERIMENTAL
Intervention: 0.5 μg.kg‐1 dexmedetomidine (DEX 0.5 group)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 1 μg.kg‐1 dexmedetomidine (DEX 1 group)
Number of subjects: 130
Study: 32306213

Group type: EXPERIMENTAL
Intervention: On-demand PrEP during the Open-Label Extension (OLE) phase
Number of subjects: 0
Study: 33935153

Group type: EXPERIMENTAL
Intervention: Physical therapy-guided movement supplemented with virtual reality
Number of subjects: 41

Group type: COMPARATOR
Intervention: Physical therapy-guided movement alone without virtual reality
Number of subjects: 41
Study: 34678758

Group type: EXPERIMENTAL
Intervention: 0.9 mg of 0.1% E2 gel per day
Number of subjects: 78

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 78
Study: 32749918

Group type: EXPERIMENTAL
Intervention: B‐Turmactive® (water‐soluble TEs and insoluble curcuminoids)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Brewer's yeast (placebo)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: B‐Turmactive®
Number of subjects: 68